- Home>
- Specialties>
- Oncology and Hematology>
- Lymphoma
Search for Lymphoma in Oncology and Hematology
Physician-authored summaries on the latest research on lymphoma, editorials on lymphoma, and perspectives on lymphoma - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 105 results - Relevance
- Date
You searched for: lymphoma in Oncology and Hematology
-
CMYC-Translocation Associated with Poor Prognosis in Relapsed DLBCL
- April 3, 2012
- Michael E. Williams, MD
- Oncology and Hematology
Patients with relapsed or refractory diffuse large B-cell lymphoma and CMYC oncogene translocations had poor outcomes after reinduction therapy and stem-cell transplantation.- Reviewing:
- Cuccuini W et al., Blood 2012 Mar 9;:
-
Early-Stage Hodgkin Lymphoma: New Lessons from an Old Study
- January 31, 2012
- Michael E. Williams, MD
- Oncology and Hematology
Overall survival was improved for patients treated with ABVD chemotherapy versus subtotal nodal irradiation.- Reviewing:
- Meyer RM et al., N Engl J Med 2011 Dec 11;: Straus DJ., N Engl J Med 2011 Dec 11;:
-
Intensive Chemotherapy for Advanced Extranodal NK/T-Cell Lymphoma
- November 1, 2011
- Michael E. Williams, MD
- Oncology and Hematology
The SMILE regimen provided high response rates.- Reviewing:
- Yamaguchi M et al., J Clin Oncol 2011 Oct 11;:
-
First-Line Rituximab for Nodular Lymphocyte-Predominant Hodgkin Lymphoma
- October 11, 2011
- Michael E. Williams, MD
- Oncology and Hematology
All patients with stage IA disease responded to therapy; 81% remained in remission at 3 years.- Reviewing:
- Eichenauer DA et al., Blood 2011 Aug 9;:
-
Comparing Chemotherapies for Advanced Hodgkin Lymphoma
- August 2, 2011
- Michael E. Williams, MD
- Oncology and Hematology
Seven-year survival rates were similar with ABVD and BEACOPP.- Reviewing:
- Viviani S et al., N Engl J Med 2011 Jul 21; 365:203.
-
Combination Therapy for Testicular Lymphoma Gives Reassuring Results
- July 12, 2011
- Michael E. Williams, MD
- Oncology and Hematology
A high rate of progression-free survival was achieved with systemic immune chemotherapy, intrathecal prophylaxis, and radiation therapy to the contralateral testis.- Reviewing:
- Vitolo U et al., J Clin Oncol 2011 Jul 10; 29:2766.
-
Marrow Involvement and Survival in Diffuse Large B-Cell Lymphoma
- May 17, 2011
- Michael E. Williams, MD
- Oncology and Hematology
DLBCL patients with positive bone-marrow biopsy at diagnosis had inferior overall survival compared with marrow-negative patients.- Reviewing:
- Sehn LH et al., J Clin Oncol 2011 Apr 10; 29:1452.
-
Attenuated Immunochemotherapy for Older Patients with Lymphoma
Nearly half of patients older than 80 with diffuse large B-cell lymphoma were in remission 2 years after receiving reduced-dose chemotherapy plus rituximab.- Reviewing:
- Peyrade F et al., Lancet Oncol 2011 May; 12:460.
-
Allogeneic Stem-Cell Transplantation for Relapsed Lymphoma
- March 22, 2011
- Michael E. Williams, MD
- Oncology and Hematology
Patients with relapsed diffuse large B-cell lymphoma after autologous STC benefited from allogeneic STC.- Reviewing:
- van Kampen RJW et al., J Clin Oncol 2011 Feb 14;:
-
Morbidity and Mortality in Hodgkin Lymphoma Survivors
- March 22, 2011
- Michael G. Douvas, MD
- Oncology and Hematology
The growing population of HL survivors is at risk for long-term complications of therapy.- Reviewing:
- Castellino SM et al., Blood 2011 Feb 10; 117:1806.
-
Maintenance Rituximab for Follicular Lymphoma
- January 25, 2011
- Michael E. Williams, MD
- Oncology and Hematology
Progression-free survival was longer with maintenance therapy than without it.- Reviewing:
- Salles G et al., Lancet 2011 Jan 1; 377:42.
-
Combination Therapy for Early Unfavorable Hodgkin Lymphoma
- November 30, 2010
- Michael E. Williams, MD
- Oncology and Hematology
Four cycles of chemotherapy plus involved-field radiotherapy were highly effective for stage I–II Hodgkin lymphoma with unfavorable clinical features.- Reviewing:
- Eich HT et al., J Clin Oncol 2010 Sep 20; 28:4199.
-
Second Malignancies in Lymphoma Patients
- November 2, 2010
- Michael E. Williams, MD
- Oncology and Hematology
Patients with small lymphocytic, follicular, or diffuse large B-cell lymphomas had excess risk for several second cancers.- Reviewing:
- Morton LM et al., J Clin Oncol 2010 Oct 12;:
-
Hepatitis B Virus Reactivation After Rituximab Therapy
- November 2, 2010
- Michael E. Williams, MD
- Oncology and Hematology
Reactivation occurred in 12% of lymphoma patients who were seropositive for prior HBV infection.- Reviewing:
- Niitsu N et al., J Clin Oncol 2010 Sep 13;:
-
Another Targeted Therapy for Non–Small-Cell Lung Cancer?
- October 27, 2010
- Lin-Chi Chen, MD, PhD
- Oncology and Hematology
Crizotinib, an anaplastic lymphoma kinase inhibitor, yielded a response rate of 57% in a phase I trial.- Reviewing:
- Kwak EL et al., N Engl J Med 2010 Oct 28; 363:1693. Hallberg B and Palmer RH., N Engl J Med 2010 Oct 28; 363:1760.
-
Hepatitis B Virus Infection and Non-Hodgkin Lymphoma
- August 17, 2010
- Michael E. Williams, MD
- Oncology and Hematology
Risk for NHL was associated with hepatitis B surface antigen positivity.- Reviewing:
- Engels EA et al., Lancet Oncol 2010 Aug 4;:
-
Comparing Two Second-Line Regimens for Non-Hodgkin Lymphoma
- August 17, 2010
- Michael E. Williams, MD
- Oncology and Hematology
Outcomes were similarly poor among patients with aggressive disease.- Reviewing:
- Gisselbrecht C et al., J Clin Oncol 2010 Jul 26;:
-
Reduced-Intensity Therapy for Early-Stage Hodgkin Lymphoma Free
- August 11, 2010
- Michael E. Williams, MD
- Oncology and Hematology
Reduced-cycle chemotherapy plus lower-dose radiotherapy was highly effective in patients with stage I or II disease and favorable prognoses.- Reviewing:
- Engert A et al., N Engl J Med 2010 Aug 12; 363:640.
-
Incidence of Thrombosis in Lymphoma Patients
- August 3, 2010
- David Green, MD, PhD
- Oncology and Hematology
Anticoagulation therapy probably benefits those with advanced disease who are undergoing cancer treatments.- Reviewing:
- Caruso V et al., Blood 2010 Jul 1; 115:5322.
-
Central Nervous System Prophylaxis for Diffuse Large B-Cell Lymphoma
- July 20, 2010
- Michael E. Williams, MD
- Oncology and Hematology
Adding high-dose methotrexate to front-line therapy limited CNS relapses in patients with high-risk DLBCL.- Reviewing:
- Abramson JS et al., Cancer 2010 Jun 8;:
Sort by:
Items 1 to 20 of 105 results - Relevance
- Date
